Cargando…

Numbers needed to treat to prevent tuberculosis

Continued research is crucial to reach elimination targets, which will be unattainable unless new tools are developed http://ow.ly/TFYNi

Detalles Bibliográficos
Autores principales:	Matteelli, Alberto, Lönnroth, Knut, Getahun, Haileyesus, Falzon, Dennis, Migliori, Giovanni Battista, Raviglione, Mario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2015
Materias:	Agora
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4664607/ https://www.ncbi.nlm.nih.gov/pubmed/26621888 http://dx.doi.org/10.1183/13993003.01179-2015

Ejemplares similares

Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion
por: Sotgiu, Giovanni, et al.
Publicado: (2015)

Global reporting on tuberculosis preventive treatment among contacts
por: Falzon, Dennis, et al.
Publicado: (2022)

Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally
por: Masini, Tiziana, et al.
Publicado: (2022)

3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review
por: Assefa, Yibeltal, et al.
Publicado: (2018)

First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
por: Tadolini, Marina, et al.
Publicado: (2016)

Universal use of face masks for success against COVID-19: evidence and implications for prevention policies
por: Esposito, Susanna, et al.
Publicado: (2020)

On tuberculosis and COVID-19 co-infection
por: Tadolini, Marina, et al.
Publicado: (2020)

Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges
por: Tadolini, Marina, et al.
Publicado: (2016)

Practices of therapeutic drug monitoring in tuberculosis: an international survey
por: Margineanu, Ioana, et al.
Publicado: (2022)

Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital
por: Stochino, Claudia, et al.
Publicado: (2020)

The impact of COVID-19 and the restoration of tuberculosis services in the Western Pacific Region
por: Chiang, Chen-Yuan, et al.
Publicado: (2020)

Impact of the SARS-CoV-2 epidemic on tuberculosis treatment outcome in Northern Italy
por: Magro, Paola, et al.
Publicado: (2020)

Video-observed treatment for tuberculosis patients in Belarus: findings from the first programmatic experience
por: Sinkou, Heorhi, et al.
Publicado: (2017)

Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study
por: Migliori, Giovanni Battista, et al.
Publicado: (2021)

Tuberculosis prevention must integrate technological and basic care innovation
por: Mason, Paul H., et al.
Publicado: (2016)

Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases
por: Tadolini, Marina, et al.
Publicado: (2020)

Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid
por: Wells, Charles D., et al.
Publicado: (2015)

A profile of a retrospective cohort of 22 patients with COVID-19 and active/treated tuberculosis
por: Gupta, Nitesh, et al.
Publicado: (2020)

Tuberculosis control, and the where and why of artificial intelligence
por: Doshi, Riddhi, et al.
Publicado: (2017)

Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives
por: Pontali, Emanuele, et al.
Publicado: (2019)

Rifapentine access in Europe: growing concerns over key tuberculosis treatment component
por: Guglielmetti, Lorenzo, et al.
Publicado: (2022)

Tuberculosis contact investigation in an intermediate burden setting: implications from a large tuberculosis contact cohort in Taiwan
por: Lee, Meng-Rui, et al.
Publicado: (2017)

In vivo microevolution of Mycobacterium tuberculosis and transient emergence of atpE_Ala63Pro mutation during treatment in a pre-XDR TB patient
por: Ghodousi, Arash, et al.
Publicado: (2022)

Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union
por: van der Werf, Marieke J., et al.
Publicado: (2017)

The potential impact of COVID-19-related disruption on tuberculosis burden
por: McQuaid, C. Finn, et al.
Publicado: (2020)

Insight into the impact of the COVID-19 epidemic on tuberculosis burden in China
por: Chen, Hongguang, et al.
Publicado: (2020)

Impact of the COVID-19 pandemic on tuberculosis laboratory services in Europe
por: Nikolayevskyy, Vladyslav, et al.
Publicado: (2021)

QIAreach QuantiFERON-TB for the diagnosis of Mycobacterium tuberculosis infection
por: Saluzzo, Francesca, et al.
Publicado: (2022)

Risk factors for mortality in patients with COVID-19 needing extracorporeal respiratory support
por: Riera, Jordi, et al.
Publicado: (2022)

Variation in policy and practice of adolescent tuberculosis management in the WHO European Region
por: Blok, Nick, et al.
Publicado: (2016)

Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients
por: Nimmo, Camus, et al.
Publicado: (2020)

JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk
por: Mehta, Puja, et al.
Publicado: (2020)

Cycloserine did not increase depression incidence or severity at standard dosing for multidrug-resistant tuberculosis
por: Tornheim, Jeffrey A., et al.
Publicado: (2022)

Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis
por: Akkerman, Onno W., et al.
Publicado: (2018)

Screening for tuberculosis among high-risk groups attending London emergency departments: a prospective observational study
por: Gupta, Rishi K., et al.
Publicado: (2021)

Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
por: Decroo, Tom, et al.
Publicado: (2022)

Accuracy of whole-genome sequencing to determine recent tuberculosis transmission: an 11-year population-based study in Hamburg, Germany
por: Diel, Roland, et al.
Publicado: (2019)

Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis?
por: Ndjeka, Norbert, et al.
Publicado: (2020)

The influence of preventive strategies on the COVID-2019 epidemic in Shenzhen, China
por: Yang, Kai, et al.
Publicado: (2020)

Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China
por: Lu, Peng, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_44h5hg6o46rkdi9rqhf6lh1jg2